REG - Assura plc - Capital Markets Event

AssuraAnnouncement

08/02/2024 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240208:nRSH4858Ca&default-theme=true

RNS Number : 4858C  Assura PLC  08 February 2024

8 February 2024

Assura plc

 

Capital markets event

 

 

Assura plc ("Assura"), the leading primary care property investor and
developer, is today hosting a capital markets presentation and site tour for
analysts and institutional investors.

 

Assura has identified several areas of emerging opportunities (NHS Trusts,
private providers, mental health and Ireland) that are now becoming meaningful
contributors to our portfolio, rental income and cash flow.

 

Members of the senior management team will present an update on our strategic
approach to these emerging opportunities, outlining why we are targeting these
areas alongside our existing GP medical centres and how our skills and
capabilities mean we are well placed to become a market leader.

 

Specifically focused on the private market, the presentation will detail:

·      The state of the UK healthcare market and resultant increasing
demand for high-quality, sustainable healthcare buildings in a community
setting

·      Overview of trends and market opportunity in the private market
segment

·      Assura's capabilities in capturing this opportunity; to
complement its existing GP centre portfolio

·      An overview of recent private market development completions

·      Recent investments and asset enhancements within the mental
health segment will also be highlighted

 

There will be a subsequent site tour to showcase Assura's recently completed,
state-of-the-art cancer care facility in Guildford.

 

Jonathan Murphy, CEO of Assura, said: "There is significant demand for
high-quality, sustainable healthcare buildings in a community setting to
alleviate the considerable and growing pressures facing the NHS whilst
improving the significantly underinvested existing estate. Each of these
emerging areas is closely aligned with Assura's existing portfolio to relieve
pressure on the health system; has attractive investment characteristics with
a strong underlying tenant covenant and offers opportunities for future
growth, which Assura is well placed to capture."

 

No new material trading information will be disclosed. A copy of the
presentation is available on the Assura plc website at:
https://www.assuraplc.com/investor-relations/reports-and-presentations
(https://www.assuraplc.com/investor-relations/reports-and-presentations)

 

- ENDS -

 

 

 Assura plc                                   Tel: 0161 515 2043
 David Purcell, Investor Relations Director   Email: Investor@assura.co.uk

 FGS Global                                   Tel: 0207 251 3801

                                            Email: Assura@fgsglobal.com
 Gordon Simpson

Grace Whelan

 

 

Notes to Editors

Assura plc is a national healthcare premises specialist and UK REIT based in
Altrincham, UK - caring for more than 600 primary healthcare buildings, from
which over six million patients are served.

 

A constituent of the FTSE 250 and the EPRA* indices, as at 30 September 2023,
Assura's portfolio was valued at £2.7 billion.

 

At Assura, we BUILD for health. Assura builds better spaces for people and
places, invests in skills and inspires new ways of working, and unlocks the
power of design and innovation to deliver lasting impact for communities -
aiming for six million people to have benefitted from improvements to and
through its healthcare buildings by 2026.

 

Assura is leading for a sustainable future, targeting net zero carbon across
its portfolio by 2040.

 

Further information is available at www.assuraplc.com
(http://www.assuraplc.com)

 

*EPRA is a registered trademark of the European Public Real Estate
Association.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUWAWRSBUURRR